Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells
Zhang-Xu He,Jin-Ling Huo,Yun-Peng Gong,Qi An,Xin Zhang,Hui Qiao,Fei-Fei Yang,Xin-Hui Zhang,Le-Min Jiao,Hong-Min Liu,Li-Ying Ma,Wen Zhao
DOI: https://doi.org/10.1016/j.ejmech.2020.112970
IF: 7.088
2021-01-01
European Journal of Medicinal Chemistry
Abstract:<p>To discover novel anticancer agents with potent and low toxicity, we designed and synthesized a range of new thiosemicarbazone-indole analogues based on lead compound <strong>4</strong> we reported previously. Most compounds displayed moderate to high anticancer activities against five tested tumor cells (PC3, EC109, DU-145, MGC803, MCF-7). Specifically, the represented compound <strong>16f</strong> possessed strong antiproliferative potency and high selectivity toward PC3 cells with the IC<sub>50</sub> value of 0.054 μM, compared with normal WPMY-1 cells with the IC<sub>50</sub> value of 19.470 μM. Preliminary mechanism research indicated that compound <strong>16f</strong> could significantly suppress prostate cancer cells (PC3, DU-145) growth and colony formation in a dose-dependent manner. Besides, derivative <strong>16f</strong> induced G1/S cycle arrest and apoptosis, which may be related to ROS accumulation due to the activation of MAPK signaling pathway. Furthermore, molecule <strong>16f</strong> could effectively inhibit tumor growth through a xenograft model bearing PC3 cells and had no evident toxicity <em>in vivo</em>. Overall, based on the biological activity evaluation, analogue <strong>16f</strong> can be viewed as a potential lead compound for further development of novel anti-prostate cancer drug.</p>
chemistry, medicinal